Abuse-Deterrent and Tamper-Resistant Opioid Formulations

  title={Abuse-Deterrent and Tamper-Resistant Opioid Formulations},
  author={Jennifer P. Schneider and Michele L. Matthews and Robert N. Jamison},
  journal={CNS Drugs},
About one in every three individuals will experience chronic pain in their lifetime, and opioids are known to be an effective means to treat this condition. Much attention, however, has been given to the fact that prescription opioid analgesics are some of the most frequently abused drugs, and misuse is prominent in patients with chronic pain. Several new opioid formulations that are designed to prevent or deter the abuse of opioids are currently in development, and two have been approved for… 

Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?

No one formulation can be expected to deter all types of opioid-abusive behaviours and no product is likely to be abuse proof in the hands of clear and determined abusers, but the reductions in abuse these new products would provide may be an incremental step towards safer prescription opioids.

Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?

The introduction of ADFs could provide a false sense of security among prescribers and dispensers, and it is feared that ADFs may have a minimal impact on non-medical use of prescription opioids.

Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.

Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.

Drug Tampering and Abuse Deterrence

The objective of this paper is to provide a summary of the types of tampering commonly performed during abuse of prescription drugs that can be useful in developing dosage forms more resistant to multiple forms of abuse.

Current Topics in Opioid Therapy for Pain Management: Addressing the Problem of Abuse

Challenges associated with improving the quality of pain care through support of prescriber education, developing formulations that combine efficacy with tamper-resistant properties, and encouraging collaborative efforts by regulatory bodies, legislators, healthcare providers, and patient advocacy groups are addressed.

Opioids and Substance Abuse

This chapter will explore the use of opioids and their potential for abuse as well as regulatory mechanisms to limit liability of their use.

Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.

Replacement of a widely prescribed opioid formulation known for its abuse potential alone may have had little impact on overall rates of prescription opioids as a class, however, changes in abuse levels of certain opioids coinciding with ADF introduction suggest possible switching of abuse among this study sample to specific long-acting opioid analgesics.

Innovative Drug Delivery and Formulation Designs To Deter Drug Abuse/Misuse Related To Suicide

This chapter reviews the design and mechanism of five successful products in the opioid and anti-psychotic categories and showcases the novel formulation tools and technologies available to deter drug abuse/misuse in patients who are at high risk of suicide.

Opioid abuse, misuse, and death: the promises and limitations of drug barrier technology now and in the future.

Drug barrier technology will be explored as well as 2 extended-release formulations recently approved by the US Food and Drug Administration of single-entity hydrocodone, a drug with extensive history of abuse and misuse since the 1940s.



Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers

It is suggested that sublingual buprenorphine and bup Renorphine/naloxone may both be abused by opioid users who are not physically dependent upon opioids, and the onset of these effects was slowed, consistent with the sublingUAL route of administration.

Effects of buprenorphine/naloxone in opioid-dependent humans

Intramuscular injection of buprenorphine/naloxone precipitates withdrawal in opioid dependent persons; therefore, the combination has a low abuse potential by the injection route in this population.

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Opioid Therapy for Chronic Noncancer Back Pain: A Randomized Prospective Study

The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep, and tapered‐off opioid treatment is palliative and without long‐term benefit.

Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.

The lack of agonist effects suggests buprenorphine has a low abuse potential in methadone-dependent patients and the lack of antagonist effects suggests it can be administered safely to subjects dependent on a low dose of methad one.

Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.

Around-the-clock controlled-release oxycodone therapy seemed to be effective and safe for patients with chronic, moderate to severe, osteo-arthritis-related pain, and effective analgesia was accompanied by a reduction in the interference of pain with mood, sleep, and enjoyment of life.